Navigation Links
Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Date:11/29/2007

PHILADELPHIA, Nov. 29 /PRNewswire/ -- As part of an ongoing commitment to help clients reduce product development times and maximize commercial impact of their products, Premier Research Group plc (AIM: PRG) announced today the consolidation of its industry-leading expertise in its core service areas into a single group, Strategic Product Development (SPD).

The expertise within the group closely matches Premier Research's focus on clinical research services in neuroscience, analgesia, oncology, infectious disease, and pediatrics. It also reflects the firm's strength in medical device development, adaptive clinical trials design, and state of the art clinical trial related technologies.

"Client demand is driving this," explained Premier Research Group COO Dr. Troy McCall. "Cost and commercialization pressures have our clients focused on leveraging the insights and expertise gained from the hundreds of studies we conduct each year. We're being asked to become involved earlier and more substantively which is great because it leads to better and more efficient studies."

Dr. McCall added that, "Strategic Product Development, in collaboration with a strong Global Regulatory Affairs capability, reflects the company's deep commitment to being a 'solution provider' for our clients. We're routinely told that this philosophy is an important differentiator for us relative to our competitors, and we've dedicated ourselves to continually building upon this strength."

The group will be led by Samer E. Kaba, MD, Vice President, Global Medical Affairs and SPD and include the following experts:
-- Bernard Brownstein, MD, Vice President, Medical Affairs and SPD --

Pediatrics

-- Luciano Fuccella, MD, Vice President, Medical Affairs and SPD --

Clinical Pharmacology

-- Danielle Giroud, RN, MBA, Vice President, SPD -- Medical Devices

-- Sid Jevons, PhD, Vice President, SPD -- Infectious Diseases

-- Mike Kuss, Vice President, SPD -- Analgesia

-- Thomas Ng, MD, MBA, CPI, Senior Director, Medical Affairs and SPD --

Hematology/Oncology

-- Ajay Sadhwani, Executive Director, SPD -- Clinical Trial Informatics

-- Bruce Stouch, PhD, Vice President, SPD -- Adaptive Trial Design

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging our commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research. Premier Research has 29 offices and operates in more than 30 countries across Europe and North America. They employ a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at a well-established network of dedicated clinical sites.


'/>"/>
SOURCE Premier Research Group plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
3. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
4. IsoTis Receives FDA Clearance for Accell Family of Products
5. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
6. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
9. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
10. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
11. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Cambridge, MA (PRWEB) , ... January 20, 2017 ... ... and scientific consulting and resource to the healthcare industry ( http://www.gandlscientific.com ), has ... to its expanding team of clinical and scientific consultants and contractors. This is ...
(Date:1/21/2017)... , Jan. 20, 2017 Interpace ... a company that provides clinically useful molecular diagnostic ... has entered into a securities purchase agreement with ... 855,000 shares of common stock in a registered ... Company has agreed to sell to the same ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
Breaking Biology News(10 mins):